Active Recombinant Human MSLN, His-tagged

• Cat.No.: MSLN-301H
• Product Overview: Recombinant Human MSLN (Accession # AAH09272) Glu296-Gly580, fused with a C-terminal 6-His tag, was produced in Mouse myeloma cell line, NS0-derived.

Specification

• Source: Mammalian cells
• Species: Human
• Tag: His
• Predicted N Terminal: Glu296
• Form: Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.
• Bio-activity: Measured by its binding ability in a functional ELISA.When Recombinant Human CA125/MUC16 is coated at 2 µg/mL (100 µL/well), the concentration of Recombinant Human Mesothelin that produces 50% of the optimal binding response is found to be approximately 0.5 - 2.5 µg/mL.
• Molecular Mass: Recombinant Human MSLN, His-tagged has a calculated MW of 33 kDa. In SDS-PAGE migrates as 40-45 kDa, reducing conditions.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Storage: Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).

Gene Information

• Gene Name: MSLN mesothelin [ Homo sapiens ]
• Official Symbol: MSLN
• Synonyms: MSLN; mesothelin; CAK1; MPF; CAK1 antigen; megakaryocyte potentiating factor; soluble MPF mesothelin related protein; pre-pro-megakaryocyte-potentiating factor; SMRP
• Gene ID: 10232
• mRNA Refseq: NM_001177355
• Protein Refseq: NP_001170826
• MIM: 601051
• UniProt ID: Q13421
• Chromosome Location: 16p13.3

Reviews

05/22/2022

Very satisfied, great product.

03/06/2022

Product is high-quality.

09/30/2021

Excellent for experiments, reliable.

Q&As

What is the primary role of MSLN in normal tissues?

MSLN is normally expressed in mesothelial cells, playing a role in cell adhesion.

How is MSLN expression altered in cancerous cells?

In cancer, MSLN expression is significantly upregulated.

In which types of cancer is MSLN overexpressed?

MSLN is overexpressed in mesothelioma, ovarian, and pancreatic cancers.

Are there any therapeutic strategies targeting MSLN in cancer treatment?

Therapies targeting MSLN include antibody-drug conjugates and CAR-T cell therapies.

How can MSLN levels be detected and measured in clinical settings?

MSLN levels can be assessed through immunohistochemistry and serum biomarker tests.

What is the prognostic significance of MSLN overexpression in cancer patients?

MSLN overexpression is often associated with poor prognosis in cancer patients.

How does MSLN contribute to cancer progression and metastasis?

MSLN promotes tumor cell proliferation, invasion, and resistance to apoptosis.